Global Intravenous Iron Drugs Market Report By Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Others), By Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Others) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2023-2032

The global demand for Intravenous Iron Drugs Market is presumed to reach the market size of nearly USD 41.33 BN by 2030 from USD 5.83 BN in 2022 with a CAGR of 24.31% under the study period 2023 - 2030.

Intravenous iron drug supplementation is the process of delivering iron to the body by inserting a tiny tube into the vein of the arm and administering a liquid solution containing iron. These drugs are superior to oral supplements as they increase the iron and Hb levels higher and faster. Other benefits of these drugs include increased energy levels and easier breathing. 

Market Dynamics

The growing incidences of chronic kidney diseases & anaemia may contribute to the growth of this market. The demand for the market is also rising due to the shifting trend from oral ferrous drugs to intravenous ferrous drugs. Moreover, increasing cases of inflammatory bowel disease (IBD) and cancer worldwide have increased demand for intravenous iron drugs, which is expected to drive market growth. The growing demand for intravenous iron drugs due to the rising research & development activities is fueling the global intravenous iron drugs market growth. Also, the increasing awareness of the diagnosis and treatment of anaemia is expected to scale up the market growth during the forecast period. However, the high cost of treatment may limit the growth of this market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of intravenous iron drugs. The growth and trends of intravenous iron drugs industry provide a holistic approach to this study. 

Market Segmentation

This section of the intravenous iron drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities. 

By Product

• Iron Dextran
• Iron Sucrose
• Ferric Carboxymaltose
• Others

By Application

• Chronic Kidney Disease
• Inflammatory Bowel Disease
• Cancer
• Others

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Intravenous Iron Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

Global Intravenous Iron Drugs Market Share by Region (Representative Graph)

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the intravenous iron drugs market include Vifor Pharma Management Ltd., AMAG Pharmaceuticals, Daiichi Sankyo Company, Ltd. (American Regent. Inc.), Sanofi S.A., Pharmacosmos A/S, Shield Therapeutics Plc, AbbVie Inc. (Allergan Plc). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.